A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days - Concepedia

Concepedia

Publication | Open Access

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

DOI Full Paper Access

257

Citations

25

References

2006

Year

Charlotte Benson, Jeff White, Johann S. de Bono, Anne O’Donnell, Florence I. Raynaud, C. Cruickshank, Helen E. McGrath, Michael Walton, Paul Workman, Stan B. Kaye,

British Journal of Cancer

References

	Year	Citations

Page 1